Medicines Co. sees Q2 income gains on strong Angiomax sales
The Medicines Company has announced an increase in its financial outcome for the second quarter of 2010, which ended June 30.

Net income was $15.4 million, compared with net income of $3.8 million for the second quarter 2009, according to the Parsippany, N.J.-based company. Its total net revenue increased to $110.1 million for the second quarter from $104.2 million for the second quarter 2009.

For its U.S. bivalirudin (Angiomax) sales, The Medicines Company said sales increased to $104.4 million compared with $98.8 million for the second quarter 2009. However, its international sales also increased—Angiomax/Angiox international net revenue increased to $5.8 million compared with $4.5 million for the second quarter 2009.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup